These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Vardeny O; Claggett B; Kachadourian J; Pearson SM; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD Circ Heart Fail; 2018 Apr; 11(4):e004745. PubMed ID: 29643067 [TBL] [Abstract][Full Text] [Related]
9. [Chinese expert consensus on clinical application of angiotension-neprilysin inhibitor in patients with heart failure]. ; Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):662-670. PubMed ID: 35856222 [TBL] [Abstract][Full Text] [Related]
10. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure]. Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045 [TBL] [Abstract][Full Text] [Related]
11. No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril. Vergaro G; Passino C; Emdin M J Am Coll Cardiol; 2019 Jun; 73(23):3037-3038. PubMed ID: 31196468 [No Abstract] [Full Text] [Related]
13. Effect of sacubitril/valsartan on cardiac filling pressures in patients with heart failure: Suggestions for statistical analysis. Okutucu S; Bursa N Int J Cardiol; 2019 Aug; 288():117. PubMed ID: 31101225 [No Abstract] [Full Text] [Related]
14. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398 [TBL] [Abstract][Full Text] [Related]
15. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Solomon SD; Claggett B; McMurray JJ; Hernandez AF; Fonarow GC Eur J Heart Fail; 2016 Oct; 18(10):1238-1243. PubMed ID: 27364182 [TBL] [Abstract][Full Text] [Related]
16. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Marques da Silva P; Aguiar C Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756 [TBL] [Abstract][Full Text] [Related]
18. Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease. James M; Manns B Circulation; 2018 Oct; 138(15):1515-1518. PubMed ID: 30354525 [No Abstract] [Full Text] [Related]